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ABSTRACT 
The  proposed  work  aimed  to  develop  a  time  dependent  programmable  pulsatile  drug  delivery  system  of  5-Fluorouracil,  intended  for  chronotherapy  in 
colorectal cancer. Various batches of tablets were prepared by direct compression method using microcrystalline cellulose (MCC). These tablets were coated 
with pH sensitive polymers like Eudragit S-100, cellulose acetate succinate(CAS) and Ethyl Cellulose (EC) at fixed concentration with different coating level 
(10% & 20%).The prepared tablets were evaluated for lag time and in vitro drug release. FTIR studies revealed that there was no interaction between drug and 
polymer. Lag time with Eudragit S-100 at (20% coating level) was 5 hrs, Cumulative drug released from the formulation ranged from 91-96% within 8-10 hrs. 
Drug released followed first order kinetics. The rapid release of the drug after a lag time consistent with requirement for chronotherapeutics was achieved. 
This approach provides a useful means for pulsatile/programmable release (with single pulse) of 5-Fluorouracil and may be helpful for patients suffering from 
cancer. 
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INTRODUCTION 
Controlled  drug  delivery  systems  are  receiving  more  and 
more attention as they control the rate of drug release and 
sustain the duration of therapy
1. Oral controlled release drug 
delivery  system  has  a  number  of  advantages  over 
conventional release delivery preparation. However they are 
not  useful  in  certain  diseases  like  cardiovascular  diseases, 
asthma,  arthritis,  and  peptic  ulcers  etc.  which  exhibit 
circadian  rhythm,  where  constant  drug  levels  are  not 
preferred but need a pulse of therapeutic concentration in a 
periodic manner which acts as push for the development of 
PDDS
2. 
A timed, pulsatile delivery system provides one or more rapid 
release pulses at predetermined lag times or at specific sites 
resulting  in  better  absorption  of  the  drug,  and  thereby 
providing more effective plasma concentration time profile
3. 
Large-amplitude  circadian  rhythms  have  been  mapped  for 
some tumors. The rhythmic circadian changes in tumor blood 
flow and cancer growth are observed, both when tumors are 
small and growing most rapidly and when they are larger and 
growing  slowly.  The  goal  of  circadian-  modulated 
chemotherapy  or “chronotherapy” is to find times for drug 
delivery  that  results  in  low  toxicity  to  the  host  and  high 
toxicity  to  the  cancer  cell,  increase  the  maximum  drug 
tolerance,  and  ultimately  result  in  better  tumor 
management
4,5. 
Colorectal  cancer  (CRC)  is  a  lifestyle-related  illness.  It 
exhibits  a  well-defined  precancerous  (usually  polypoid) 
growth phase that progresses in parallel with a characteristic 
sequence of molecular genetic changes
6.  
5-  Fluorouracil  is  a  antineoplastic  drug  which  is  white  in 
colour and crystalline. Its molecular formula is C4H3FN2O2 
and  is  distributed  throughout  the  body  tissue  and  fluids 
including  crossing  the  blood-brain  barrier  to  appear  in  the 
cerebrospinal  fluid  and  disappear  from  the  plasma  within 
about 3 hours
7. 
MATERIALS AND METHODS 
5- Fluorouracil was obtained as a gift sample from Naprod 
Life Sciences Pvt. Ltd. (Mumbai, India). Eudragit S-100 was 
obtained  as  gift  samples  from  Evonik  Pvt.  Ltd.  Mumbai. 
Ethyl cellulose was gifted by Colorcon Asia Pvt. Ltd., (Goa, 
India).  Cellulose  acetate  succinate  was  gifted  by  Arihant 
trading,  Mumbai.  Microcrystalline  cellulose,  Crospovidone, 
Croscarmellose  sodium  and  Sodium  starch  glycolate  was 
gifted by Cipla Ltd. Mumbai. All other excipients used were 
of analytical grade. 
Preformulation studies of pure drug 
Identification of 5- Fluorouracil was carried out by Infrared 
Absorption Spectroscopy. 
Preparation of core tablet 
Tablets of 5- Fluorouracil were made by direct compression 
method. All ingredients were weighed accurately and blended 
homogeneously  for  15  minutes  by  trituration  using  glass 
mortar  and  pestle.  Microcrystalline  cellulose  (MCC)  was 
used  as  direct  compressing  agent.  Crospovidone, 
Croscarmellose Sodium and Sodium Starch Glycolate were 
used as disintegrating agents. Aerosil and Talc were used as 
lubricants.  Tablets  were  compressed  in  Minipress  Tablet 
Compression  Machine using  8mm round  concave  punches. 
(Rimek  minipress-11  MT,  Karnavati  Engineering  Ltd., 
Ahmedabad, India). The composition of core tablets is given 
in Table 1. 
Evaluation of powder blend  
Blended drug/polymer mixture of all the formulations were 
subjected for precompressional evaluation such as bulk and 
tapped  density,  compressibility  index  Hausner’s  Ratio  and 
angle of repose
8. 
Evaluation of Core Tablets 
Prepared core tablets were evaluated for physical properties 
like uniformity of weight determined by using a Sartorious 
electronic balance (Model CP- 224 S), hardness by using a 
dial  type  hardness  tester  (Model  1101,  Shivani  Scientific 
Ind),  friability  by  using  a  Roche  friabiliator  (Camp-bell 
Electronics,  Mumbai),  disintegration  time  by  using  a 
disintegration  test  apparatus  (Electrolab  ED-2  Bowl  USP, 
Mumbai), diameter and thickness by using vernier caliper etc. 
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Table 1. Composition of 5- Fluorouracil core tablets 
Ingredients 
(mg/tablet) 
Formulations 
F1           F2      F3 
5- Fluorouracil  50  50  50 
Microcrystalline cellulose  65  65  65 
Lactose  129  129  129 
Crospovidone  2  *  * 
Croscarmellose sodium  *  2  * 
Sodium starch glycolate  *  *  2 
Talc  2  2  2 
Aerosil  2  2  2 
Total  250  250  250 
 
Tablet dosage forms assay  
Tablet containing 50 mg of drug was dissolved in 100 ml of 
phosphate  buffer  pH  6.8  and  7.4  (simulated  intestinal  & 
colonic fluid respectively). The drug was allowed to dissolve 
in the solvent, the solution was filtered, and 1ml of filtrate 
was  suitably  diluted  with  respective  buffer  and  analyzed 
spectrophotometrically  at  266  nm.  The  amount  of  5- 
Fluorouracil  was  estimated  by  using  standard  calibration 
curve of the drug. Drug content studies were carried out in 
triplicate for each batch of formulation
9. 
In vitro disintegration test for tablet 
 
The in vitro disintegration time of a tablet was determined 
using disintegration test apparatus. Place one tablet in each of 
the 6 tubes of the basket.  Add a disc to each tube and run the 
apparatus using pH 6.8 SIF (simulated intestinal fluid) and 
pH 7.4 SCF (simulated colonic fluid) maintained at 37
0±2
0C 
as the immersion liquid.  The assembly should be raised and 
lowered  between  30  cycles  per  minute  in  the  pH  6.8 
maintained  at  37
0±2
0C.    The  time  in  seconds  taken  for 
complete disintegration of the tablet with no palpable mass 
remaining in the apparatus was measured and recorded. The 
experiment was carried out in triplicate
10. 
Preparation of enteric coated tablet 
Preparation of coating solution 
Coating  solution  was  made  using  different  pH  sensitive 
polymers like Eudragit S100, Cellulose acetate succinate and 
Ethyl cellulose. Polymeric content in the coating solution was 
kept  constant  as  10%w/v.  Required  quantity  of  polymers 
were dissolved in mixture of solvents (acetone & isopropyl 
alcohol) and stirred on magnetic stirrer to get homogeneous 
coating  solution.  Dibutyl  phthalate  was  added  in  above 
solution as plasticizer (2% as polymer based) and Titanium 
dioxide (5% as polymer based) was added as an opacifying 
agent.  After  getting  homogeneous  coating  solution  coating 
was done on tablets. 
The process conditions were as follows: 
Table 2. Detail list of Parameter Value 
Parameter    Value 
Inlet temperature    40-45 
0C 
Exhaust temperature    30-35 
0C 
Spray rate    3-5 ml /min 
Spray nozzle diameter    1 mm 
Distance (Tablet bed-spray 
gun) 
  10 – 15 cm 
Pan speed(RPM)    20 
 
The core tablets were coated with above coating solution at 
coating level of 14 % and 24 % respectively on basis of % 
weight gain by core tablet.  
The  %  weight  gain  calculated  by  using  the  following 
equation:  
 
Where Wt is the weight of the tablets after coating, W0 is the 
initial weight of tablets. The tablets were dried in an oven at 
50
oC  for  12  hr  and  these  tablets  were  subjected  for 
evaluation.  Composition  of  coating  solution  is tabulated in 
Table 3. 
 
Table 3. Composition of coating solution. 
1Quantity in gms  
2Quantity in ml 
Ingredients  CT 
1 
CT 
2 
CT 
3 
CT 
4 
CT 
5 
CT 
6 
1Eudragit S 100  50  50  *  *  *  * 
1Cellulose acetate 
succinate 
*  *  50  50  *  * 
1Ethyl cellulose  *  *  *  *  50  50 
2Dibutyl phthalate  1  1  1  1  1  1 
1Titanium dioxide  2.5  2.5  2.5  2.5  2.5  2.5 
2Isopropyl alcohol  250  250  250  250  250  250 
2Acetone  250  250  250  250  250  250 
% Coating  14  24  14  24  14  24 
 
Evaluation of pulsatile release tablets 
Dissolution studies of the coated tablets  
Drug release studies of coated tablets were carried out using 
USP XXIII dissolution test apparatus I. Initially tablets were 
placed  in  900  ml  of  0.1  N  HCl  for  2 hours maintained  at 
37±0.5
0C, 75 rpm followed by pH 6.8 phosphate buffer for 3 
hours  and  pH  7.4  for  5  hours.  Aliquots  of  predetermined 
quantity  were  collected  manually  at  definite  time  intervals 
replacing  with  fresh  buffer  to  maintain  sink  condition  and 
analysed  for  drug  content  using  a  UV-visible 
spectrophotometer at λ max of 266 nm
11. 
Data analysis  
To analyse the mechanism for the drug release and release 
rate kinetics of the dosage form, the data obtained from in 
vitro drug release studies was fitted in to zero order and first 
order
12. 
RESULTS AND DISCUSSIONS: 
Drug polymer compatibility studies were conducted by FTIR 
spectroscopy  and  the results are  presented  in  figure  1  and 
figure 2. The results indicated that were was no interaction 
between the drug and the polymers.  
Evaluation of powder blend 
Angle of repose, compressibility index and Hausner’s ratio 
were found to be between 20.33 to 22.22, 12 to 12.30 and 
1.21 for all formulations respectively. These results suggested 
that powder blend had good flow properties. 
Evaluation of core tablets 
The  formulated  tablets  were  subjected  for  evaluation 
according  to  official  specifications  for  shape,  thickness, 
hardness,  friability,  weight  variation,  drug  content  and  in 
vitro disintegration time. The results are tabulated in Table 3. 
In vitro disintegration for batch F1, F2 & F3 was found to be 
35, 50 & 55 seconds respectively. Batch F1 was considered 
as  optimum  formulation  as  it  showed  least  disintegration 
time. Hence further study was planned using formulation F1 
as core tablet. 
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Figure 2:  IR spectrum of drug + MCC + Crospovidone + Lactose 
 
Table 4. Post-compression evaluation of the prepared tablets 
Batch  F1  F2  F3 
Uniformity of thickness (mm) 
(n=3) 
4.3 ± 0.1  4.2 ± 0.2  4.1 ± 0.1 
Weight variation (mg) (n=10)  250 ± 2.23  252 ± 2.32  248 ± 2.45 
Hardness (kg/cm2 ) (n=3)  4.3 ± 0.2  4.5 ± 0.2  4.1± 0.2 
Friability (%) (n=6)  0.84 ± 0.05  0.80 ± 0.05  0.86 ± 0.05 
% Drug content (n=3)  96.21 ± 
0.23 
96.16 ±0.25  96.33±0.34 
Disintegration time (sec)  35  50  55 
 
Evaluation of pulsatile release tablets 
In vitro drug release studies 
All  the  pH  sensitive  polymers  used  in  the  present  study  ( 
Eudragit  S-100,  Ethyl  cellulose  and  Cellulose  Acetate 
Succinate) showed no drug release in the first two hrs in the 
gastric environment. Later a different drug release profile was 
evident for each polymer. 
A  plot  of  %  drug  release  versus  time  showed  that  the 
dissolution  rate  was  inversely  proportional  to  the  coating 
level  applied.  Lag  time  of  3  hours  was  achieved  with  a 
coating level of 10% (CT 1- Eudragit S 100) and the % drug 
release  in  the  initial  3  hrs  of  dissolution  media  pH  6.8 
phosphate  buffer  was  72.32%.  As  the  coating  level  was 
increased  to  20  %  (CT-2-  Eudragit  S  100),  there  was  a 
significant increase in the lag time upto 5 hrs and there was 
absolutely no drug release in pH 6.8 phosphate buffers. At 6
th 
hr,  burst  effect  was  observed  it  was  because  coating 
concentration  was  increased  and  the  coat  became  more 
impermeable and finally retarded the drug release.     
The  formulation  with  10  %  coating  level  (CT  3  Cellulose 
Acetate Succinate- CAS) showed a lag time of 2 hrs and % 
drug  release  in  initial  3  hrs  of  dissolution  media  pH  6.8 
phosphate  buffer  was  60.32%.  As  the  coating  level  was 
increased to 20% (CT 4 CAS) the lag time was increased to 4 
hrs and inversely the drug release was reduced to 35.64%. All 
the coated tablets showed a nearby complete drug release in 
10 hrs. 
A lag time of 3 hours was achieved with a coating level of 
10% (CT 5 Ethyl cellulose-EC) and the % drug release in the 
initial 3 hrs of dissolution media pH 6.8 phosphate buffer was 
77.08%. As the coating level was increased to 20% (CT 6- 
EC), there was a significant increase in the lag time upto 5 
hrs  and  there  was  absolutely  no  drug  release  in  pH  6.8 
phosphate buffer. Drug release started in pH 7.4 dissolution 
media. This may be attributed to the fact as the coating level 
was increased, the drug release was retarded suggesting that 
the thicker film formed by EC was quiet impermeable in pH 
6.8 phosphate buffer solution. 
The lag time and in vitro drug release profiles for all three 
polymer  solutions  at  constant  concentration  and  variable 
coating levels indicate that lag time is directly proportional 
and dissolution rate is inversely proportional to the coating 
level applied. At a coating level of 20% of Eudragit S 100 
(CT 2) and Ethyl cellulose (CT 6) are proved to be the most 
appropriate pH sensitive polymers for pulsatile drug delivery.  
The  drug  release  profile  showed  sigmoidal  release  pattern 
which  is  considered  to  be  an  ideal  for  the  pulsatile  drug 
delivery system as shown in figures 3, 4 and 5. 
The results of in vitro dissolution studies obtained from these 
formulations  were  plotted  in  zero  order  and  first  order 
kinetics to study the mechanism of drug release. Correlation 
coefficient  (r)  value  was highest  for  the  first  order release 
equation in all the 6 batches thus indicating first order release 
kinetics which is depicted in figure 6. 
 
 
Figure 3:  in vitro drug release profile of Eudragit S-100 
 
 
Figure 4:  in vitro drug release profile of Cellulose Acetate Succinate 
 
 
Figure 5:  in vitro drug release profile of Ethyl cellulose 
 
 
Figure 6:  First order kinetics plots of formulations 
 
CONCLUSION 
Finally  a  successful  attempt  was  made  to  formulate  and 
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release the drug in a controlled manner for prolonged period 
of time after a lag time as required for chronotherapy. pH 
sensitive  polymers  delayed  the  drug  release.  Thus  this 
approach  can  provide  a  useful  means  for 
pulsatile/programmable  release  (with  single  pulse)  of  5- 
Fluorouracil  and  may  helpful  for  patients  suffering  Colo 
rectal cancer. 
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